Geneyx analyzes and manages diverse, clinical, and genetic data, realizing the vision of precision medicine target drug discovery. Geneyx provides a superior analysis platform to 50 hospitals.

Geneyx's technology is based on exclusive access to GeneCards suite the leading biomedical knowledgebase.



Our Representatives

Dvir Dahary

CSO, Geneyx

CSO

Geneyx

RAVIV ITZHAKY

Co-Founder CMO, Geneyx

Co-Founder CMO

Geneyx

Geneyx collects, analyzes, and monetizes diverse, integrated clinical and genetic data for pharma drug discovery Raviv, Co-founder, and CMO of Geneyx, is a leading advertising, marketing...

Company Solutions

Geneyx - The Whole Genome Company

When it comes to the analysis and interpretation of the sequenced whole human genome – Geneyx Analysis, our AI-based platform, is the first and best choice for hospitals, genetic labs, translational and early target discovery researchers at Pharma. Powered by the comprehensive and popular GeneCards Knowledgebase Suite, it provides clinicians with accurate and rapid diagnoses with double the diagnostic yield, while reducing turn-around time to minutes.

Geneyx’s technology provides biomedical interpretation capabilities for more than 18% of the genome (more than 10x the protein-coding scope), and continually provides new solutions for enhancing this scope. This enables researchers to better leverage the power of whole-genome sequencing data and distill novel findings that will lead to the development of the next generation of targeted and personalized therapeutics and diagnostics.

Much of the genetic data generated today is silo’d in hospitals around the world and can be better used by researchers in targeted therapeutic development. Geneyx’s platform provides hospitals with better diagnostics, and the opportunity to support the development of these novel therapeutics that will offer better care for their patients.

Looking For

Collaboration partners

Hospitals. Genetic labs Biotechnology. Pharma research. Translational research. Cardiovascular specialists

Academy research.